Novel Cyclic Lipopeptide Antibiotics: Effects of Acyl Chain Length and Position
Multidrug-resistant bacteria are a global health problem. One of the last-resort antibiotics against Gram-negative bacteria is the cyclic lipopeptide colistin, displaying a flexible linker with a fatty acid moiety. The aim of the present project was to investigate the effect on antimicrobial activit...
Saved in:
Published in | International journal of molecular sciences Vol. 21; no. 16; p. 5829 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
MDPI AG
13.08.2020
MDPI |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Multidrug-resistant bacteria are a global health problem. One of the last-resort antibiotics against Gram-negative bacteria is the cyclic lipopeptide colistin, displaying a flexible linker with a fatty acid moiety. The aim of the present project was to investigate the effect on antimicrobial activity of introducing fatty acid moieties of different lengths and in different positions in a cyclic peptide, S3(B), containing a flexible linker. The lipidated analogues of S3(B) were synthesized by 9-fluorenylmethoxycarbonyl (Fmoc) solid-phase peptide synthesis. Following assembly of the linear peptide by Fmoc solid-phase peptide synthesis, on-resin head-to-tail cyclization and fatty acid acylation were performed. The antimicrobial activity was determined against the ESKAPE pathogens,
,
,
,
, and
. Furthermore, hemolytic activity was determined against human erythrocytes. A total of 18 cyclic lipopeptides were synthesized and characterized. It was found that introduction of fatty acids in positions next to the flexible linker was more strongly linked to antimicrobial activity. The fatty acid length altered the overall hydrophobicity, which was the driving force for both high antimicrobial and hemolytic activity. Peptides became highly hemolytic when carbon-chain length exceeded 10 (i.e., C
), overlapping with the optimum for antimicrobial activity (i.e., C
-C
). The most promising candidate (C
)
showed antimicrobial activity corresponding to that of S3(B), but with an improved hemolytic profile. Finally, (C
)
was further investigated in a time-kill experiment. |
---|---|
Bibliography: | Current address: Novo Nordisk A/S, Krogshøjvej 44, 2820 Bagsværd, Denmark. |
ISSN: | 1422-0067 1661-6596 1422-0067 |
DOI: | 10.3390/ijms21165829 |